CTLT News and Press, Catalent Inc.

2024-06-30 17:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-28 07:15:04 ET Barclays analyst issues EQUAL-WEIGHT recommendation for CTLT on June 28, 2024 05:28AM ET. The previous analyst recommendation was Equal-Weight. CTLT was trading at $56.41 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-06-26 09:10:26 ET More on Sarepta Therapeutics Sarepta Therapeutics: Pushing The Edge And Creating The Horizon Sarepta Therapeutics: Why Today's Rally On DMD Drug Label Expansion Won't Last Sarepta Therapeutics: Navigating Elevidys Upside Potential Trend...

2024-06-25 10:40:00 ET Summary TimesSquare Capital Management, LLC is a fundamental research-oriented growth equity investment management firm specializing in growth equity strategies for institutional investors. TimesSquare uses a well-established team approach to growth investing th...

2024-06-25 09:00:00 ET Summary Catalent stock rose 3% after Elevidys label expansion approval by the FDA. Sarepta's stock reached an all-time high after Elevidys label expansion approval. Several companies including PFE, CAPR, RGNX, SLDB, VRTX, have DMD gene-therapy product candid...

Catalent, Inc. (NYSE: CTLT) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 3.37% on the day to $56.66. Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologi...

2024-06-21 10:03:58 ET More on Catalent Catalent shareholders approve acquisition by Novo Holdings Catalent, Novo Nordisk receive FTC request for more information Seeking Alpha’s Quant Rating on Catalent Historical earnings data for Catalent Fi...

2024-06-10 19:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-04 16:12:36 ET Summary Medpace Holdings is a US-based clinical research organization that is well-positioned to benefit from increased demand due to geopolitical risks affecting Chinese firms. Medpace stands out among its peers due to its growth orientation, competitive ma...

2024-05-29 10:18:39 ET More on Novo Nordisk, Catalent Catalent - Novo Holdings Merger: Attractive Spread Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Consid...